Adma Biologics earnings were $209.4M for the trailing 12 months ending Sep 30, 2025, with 203.4% growth year over year. The latest ADMA earnings report on Sep 30, 2025 announced Q3 2025 earnings of $36.4M, up 6.5% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ADMA reported annual earnings of $197.7M, with -800% growth.
ADMA past earnings growth
How has ADMA's earnings growth performed historically?
On ADMA's earnings call on Invalid Date, Adma Biologics (NASDAQ: ADMA) reported Q3 2025 earnings per share (EPS) of $0.15, up 0% year over year. Total ADMA earnings for the quarter were $36.43 million. In the same quarter last year, Adma Biologics's earnings per share (EPS) was $0.15.
As of the last Adma Biologics earnings report, Adma Biologics is currently profitable. Adma Biologics's net profit (also called net income) for the twelve months ending Sep 30, 2025 was $209.45 million, a 207.41% increase year over year.
What was ADMA's earnings growth in the past year?
As of Adma Biologics's earnings date in Invalid Date, Adma Biologics's earnings has grown 203.45% year over year. This is 137.14 percentage points higher than the US Biotechnology industry earnings growth rate of 66.31%. ADMA earnings in the past year totalled $209.45 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.